NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹2,000.00.
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (SPARC) – INVESTOR SUMMARY HEADLINE NUMBERS • Q1 FY2027 Standalone Loss: ₹2,098 lakhs (unaudited), comp | 2026-08-10 |
| Quarterly results · Q4 FY26 SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (SPARC) - FINANCIAL SUMMARY HEADLINE NUMBERS • Year ended March 31, 2026 audited results approved by Bo | 2026-05-18 |
| Quarterly results · Q3 FY26 SPARC (SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED) - Q3 FY2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q3 FY2026 Standalone Revenue from Operations: | 2026-02-09 |
| Investor presentation · Q3 FY26 SPARC R&D DAY INVESTOR SUMMARY HEADLINE NUMBERS • Company: Sun Pharma Advanced Research Company Limited (SPARC) • Call Date: January 8, 2026 • Two l | 2026-01-13 |
| Investor presentation | 2026-01-08 |
| Quarterly results · Q2 FY26 SPARC (SUN PHARMA ADVANCED RESEARCH COMPANY) – FINANCIAL SUMMARY H1 FY2025-26 (Half Year Ended September 30, 2025) --- HEADLINE NUMBERS • Revenue f | 2025-11-10 |
| Quarterly results · Q1 FY26 SPARC (Sun Pharma Advanced Research Company Limited) - Q1 FY2025-26 Results Summary HEADLINE NUMBERS • Board approved unaudited standalone and conso | 2025-08-04 |
| Annual report FY2025 SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (SPARC) – ANNUAL REPORT 2024-25 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹7,176.60 lakhs (FY | 2025-07-18 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sun Pharma Advanced Research Company Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.